iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Q2FY24 Preview: Divi's Laboratories: Revenue seen at Rs. 19,128 million, PAT at Rs. 4,216 million

2 Nov 2023 , 10:28 AM

Result date: November 6, 2023

Recommendation: Reduce

Target price: Rs. 3,055

Analysts at IIFL Capital Services expect Divi’s Laboratories to post 3% growth in revenue as compared to the year-ago quarter. They are baking in Nil contribution from Molnu in the September 2023 quarter versus USD 37 million in the year-ago quarter. Ex-Molnu CS revenue could grow 45% as compared to the year-ago quarter, owing to depressed base of last year.

Profit After Tax or PAT is likely to decline 15% over the year-ago quarter.

Rs. Million

September 2023 estimates

YoY change

QoQ change

Revenue 

19,128

3.1%

7.6%

EBITDA

6,025

(3.0)%

19.6%

EBITDA margin (%)

31.5%

(199) bps

315 bps

Profit After Tax 

4,216

(14.6)%

18.4%

Source: IIFL Research

Related Tags

  • Divi's Laboratories Q2
  • Divis laboratories
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.